References
- Chan C, Montaner J, Lefebvre E-A, Morey G, Dohn M, McIvor RA, Scott J, Marina R, Caldwell P. Atovaquone suspension compared with aerosolized pentamidine for prevention of Pneumocystis carinii pneumonia in human inmunodeficiency virus-infected subjects intolerant of trimethoprim or sulfonamides. J Infect Dis 1999; 180: 169–176
- Dahlbäck M. Behavior of nebulizing solutions and suspensions. J Aerosol Med 1994; 7: S13–S18
- Dennis JH, Nierbrink O. New nebulzer technology. Drug delivery to the lung, H Bisgaard, CO O'Callagan, GC Smaldone. Marcel Dekker, New York 2002; 303–336
- El-Sadr WM, Murphy RL, McCabe Yurik T, Luskin-Hawk R, Cheung TW, Balfour HH, Eng R, Hooton TM, Kerkering TM, Schutz M. Atovaquone compared with Dapsone for the prevention of Pneumocystis carinii pneumonia in patients with HIV infection who cannot tolerate trimethoprim, sulfonamides, or both. New Eng J Med 1998; 339: 1889–1995
- Gonda I. A semi-empirical model of aerosol deposition in the human respiratory tract for mouth inhalation. J Pharm Pharmacol 1981; 33(11)692–696
- Hughes W, Leoung G, Kramer F, Bozzette SA, Safrin S, Frame P, Clumeck N, Masur H, Lancaster D, Chan C. Comparison of Atovaquone (566C80) with trimethoprim-sulfamethoxazole to treat Pneumocystis Carinii pneumonia in patients with AIDS. New Eng J Med 1993; 328: 1521–1527
- Hughes WT, LaFon SW, Scott JD, Masur H. Adverse events associated with trimethoprim-sulfamethoxazole and atovaquone during the treatment of AIDS-related Pneumocystis carinii pneumonia. J Infect Dis 1995; 171: 1295–1301
- Jacobs C, Müller RH. Production and characterization of a budesonide nanosuspension for pulmonary administration. Pharm Res 2002; 19: 189–194
- Kaneshiro ES, Sul D, Basselin M, Kayser O. Pneumocystis carinii synthesizes four ubiquinone homologs: Inhibition by atovaquone and buparvaquone but not by stigmatellin. J Eukaryot Microbiol 2001, Suppl: 1725–1733
- Knoch M, Sommer E. Jet nebulizer design and function. Eur Respir Rev 2000; 10: 183–186
- McCallion ONM, Taylor KMG, Thomas M, Taylor AJ. Nebulization of fluids of different physicochemical properties with air-jet and ultrasonic nebulizers. Pharm Res 1995; 12: 1682–1688
- McCallion ONM, Taylor KMG, Bridges PA, Thomas M, Taylor AJ. Jet nebulisers for pulmonary drug delivery. Int J Pharm 1996; 130: 1–11
- Müller RH, Becker R, Kruss B, Peters K. 1999. Pharmaceutical nanosuspensions for medicament administration as system of increased saturation solubility and rate of solution. US patent 5,858,410
- Müller RH, Jacobs C, Kayser O. Nanosuspensions as particulate drug formulations in therapy rationale for development and what we can expect for the future. Adv Drug Deliv Rev 2001; 47: 3–19
- O'Riordan TG. Formulations and nebulizer performance. Respir Care 2002; 47: 1305–1312
- O’ Callaghan C, Barry PW. The science of nebulised drug delivery. Thorax 1997; 52: S31–S44
- Ostrander KD, Bosch WH, Bondanza DM. An in-vitro assessment of a nanocrystal (beclomethasone dipropionate colloidal dispersion via ultrasonic nebulization. Eur J Pharm Biopharm 1999; 48: 207–215
- Rosenberg DM, McCarthy W, Slavinsky J, Chan CKN, Montaner J, Braun J, Dohn MN, Caldwell PT. Atovaquone suspension for treatment of Pneumocystis carinii pneumonia in HIV-infected patients. AIDS 2001; 15: 211–214
- Saah AJ, Hoover DR, Peng Y, Phair JP, Visscher B, Kingsley LA, Schrager LK. 1995. Predictors for failure of Pneumocystis carinii pneumonia profilaxis. Multicenter AIDS Cohort Study. JAMA 273:1197–1202
- Steckel H, Eskandar F. Factors affecting aerosol performance during nebulization with jet and ultrasonic nebulizers. Eur J Pharm Sci 2003; 19: 443–455
- Wakefield AE. Pneumocystis carinii. Br Med Bull 2002; 61: 175–188